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Botulinum neurotoxin type A (BoNTA) is produced by the Gram-positive anaerobic bacterium Clostridium botulinum (1) 
and has long been used in the treatment of disorders characterized 
by increased muscle tone. It is well known that, when injected intra-
muscularly, the toxin inhibits the exocytotic release of acetylcholine 
at the neuromuscular junction, leading to muscle relaxation (2). 
Interestingly, pain relief occurs before muscular relaxation or in areas 
with no muscle tension (3), indicating that different mechanisms are 
responsible. In addition, an analgesic effect has also been observed in 
patients with pain treated using BoNTA (4,5) and in experimental 
pain studies involving animals and humans (6-8). BoNTA has been 
found to be efficient in painful conditions including neuropathic 
pain (9-11), low back pain (12), myofascial pain (13,14), fibromyal-
gia (15), trigeminal neuralgia (16), postherpetic neuralgia (17), 
headaches (18) and migraine (19,20). Although BoNTA is effective 
in several pain conditions, as mentioned above, migraine is the only 
approved condition, while the remaining conditions continue to be 
treated off-label. Most of the proposed mechanisms underlying anal-
gesic effects of the toxin are based on in vivo animal models (8,21-
23) and in vitro culture systems (24-29), which have shown that 
BoNTA is able to suppress the local release of substances involved 
in pain and vasodilation including glutamate (23), substance P 
(SP) (21,25) and calcitonin gene-related peptide (CGRP) (29). It 
has been suggested that this phenomenon may contribute to the 
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BACKGROUND: The analgesic action of botulinum neurotoxin type A 
(BoNTA) has been linked to the blockade of peripheral release of neuro-
peptides and neurotransmitters in animal models; however, there is no 
direct evidence of this in humans. 
OBjECTIVES: To investigate the effect of BoNTA on glutamate release 
in humans, using an experimental model of pain and sensitization pro-
voked by capsaicin plus mild heat. 
METHODS: Twelve healthy volunteers (six men, six women) were pre-
treated with BoNTA (10 U) on the volar forearm and with a saline control 
on the contralateral side. Dermal microdialysis was applied one week later 
to collect interstitial samples before and after the application of a capsaicin 
patch (8%) plus mild heat (40°C/60 min) to provoke glutamate release, 
pain and vasodilation. Samples were collected every hour for 3 h using 
linear microdialysis probes (10 mm, 100 kD). Dialysate was analyzed for 
glutamate concentration. Pain intensity and skin vasomotor reactions 
(temperature and blood flow changes) were also recorded. 
RESULTS: BoNTA significantly reduced glutamate release compared 
with saline (P<0.05). The provoked pain intensity was lower in the 
BoNTA-pretreated arm (P<0.01). The reduction in pain scores was not 
correlated with glutamate level. Cutaneous blood flow (P<0.05), but not 
cutaneous temperature (P≥0.05), was significantly reduced by BoNTA. 
There was a correlation between glutamate level and skin blood flow 
(r=0.58/P<0.05) but not skin temperature (P≥0.05). No differences 
according to sex were observed in any response. 
CONCLUSIONS: The present study provided the first direct evidence sup-
porting the inhibitory effect of BoNTA on glutamate release in human skin, 
which is potentially responsible for some of the analgesic action of BoNTA.
Key Words: Botulinum neurotoxin type A; Capsaicin; Glutamate; Human 
experimental pain model; Microdialysis; Vasodilation
Le blocage de la libération du glutamate par la 
neurotoxine botulique de type A chez les 
humains : une étude de microdialyse cutanée
HISTORIQUE : L’action analgésique de la neurotoxine botulique de 
type A (NBdTA) est liée au blocage de la libération périphérique des neu-
ropeptides et des neurotransmetteurs. Cependant, il n’y en a pas de preuves 
directes chez les humains.
OBjECTIFS : Examiner l’effet de la NBdTA sur la libération du glutamate 
chez les humains, au moyen d’un modèle expérimental de douleur et de 
sensibilisation provoquées par la capsaïcine et une chaleur légère.
MÉTHODOLOGIE : Douze volontaires en bonne santé (six hommes, six 
femmes) ont reçu un traitement préalable à la NBdTA (10 U) sur l’aspect 
antérieur de l’avant-bras et une injection de soluté physiologique du côté 
controlatéral. La microdialyse cutanée a été appliquée une semaine plus 
tard pour recueillir des échantillons interstitiels avant et après l’application 
d’un timbre de capsaïcine (8 %) associé à une chaleur légère (40 °C pen-
dant 60 minutes) pour provoquer une libération de glutamate, de la dou-
leur et une vasodilatation. Les échantillons ont été recueillis toutes les 
heures pendant trois heures au moyen de sondes pour microdialyse linéaire 
(10 mm, 100 kD). Le dialysat a été analysé pour déterminer la concentra-
tion de glutamate. L’intensité de la douleur et les réactions vasomotrices 
cutanées (températures et modifications du débit sanguin) ont également 
été enregistrées.
RÉSULTATS : La NBdTA réduit la libération de glutamate beaucoup plus 
que le soluté physiologique (P<0,05). L’intensité de la douleur provoquée 
était plus faible dans le bras prétraité par NBdTA (P<0,01). La réduction 
des indices de douleur n’était pas corrélée avec le taux de glutamate. La 
NBdTA réduisait considérablement le débit sanguin cutané (P<0,05), mais 
pas la température cutanée (P≥0,05). Il y avait une corrélation entre le 
taux de glutamate et le débit sanguin cutané (r=0,58/P<0,05), mais pas la 
température cutanée (P≥0,05). Aucune des réponses ne comportait de dif-
férence en fonction du sexe. 
CONCLUSIONS : La présente étude a fourni les premières preuves 
directes de l’effet inhibiteur de la NBdTA sur la libération de glutamate sur 
la peau humaine, potentiellement responsable de l’action analgésique de la 
NBdTA.
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inhibition of peripheral sensitization and pain and, possibly, prevent 
central sensitization (27,30). 
Glutamate is a well-known excitatory neurotransmitter with an 
important mediatory and modulatory role in nociception and sensitiz-
ation (31,32). It has been previously shown that activation of periph-
eral glutamate receptors contributes to nociception and peripheral 
sensitization (33-35). Moreover, an increased glutamate level is 
known to be involved in a number of painful conditions such as 
migraine and fibromyalgia (36,37). Blockade of glutamate release by 
BoNTA has only been investigated in animal models, and there is no 
evidence regarding whether similar phenomenon would occur in 
humans following pretreatment with BoNTA. Therefore, the present 
study investigated this in humans using dermal microdialysis.
The microdialysis technique has long being used to examine meta-
bolic changes or dynamic patterns of substance release (eg, glutamate 
[38,39]) in different tissues under physiological or pathological condi-
tions (40-42). Previously, it has been shown that capsaicin stimulation 
provokes release of glutamate from primary afferent fibres in rats (43). 
Thus, we designed an experimental model of pain evoked by capsaicin 
plus mild heat in healthy volunteers to provoke glutamate release and 
to further investigate potential inhibitory action of BoNTA on gluta-
mate release in humans. 
We hypothesized that intradermal injection of BoNTA alters the 
release of glutamate in human skin. The aims of the present study 
were: to investigate glutamate release following application of a top-
ical capsaicin patch (8%) plus mild heat; and to examine the effect of 
BoNTA on the evoked pain and vasomotor responses (temperature 
and blood flow) and glutamate release. The present study is the first to 
apply microdialysis to directly investigate the inhibitory effect of 
BoNTA on glutamate release in human skin.
METHODS
Subjects
The group of healthy volunteers consisted of six men (mean [± SEM] 
age 25.0±1.5 years) and six women (mean age 25.7±0.72 years), who 
were recruited among students through advertisements at Aalborg 
University, Aalborg, Denmark. Participants were informed about the 
experimental procedures, safety issues, goals and perspectives of the 
research and provided written informed consent before the start of the 
experiments. 
Study design
The study was designed as a double-blinded, randomized, placebo-
controlled trial, and was approved by the local ethics committee 
(Region of North Jutland, Denmark; N-20110075) and the Danish 
data protection agency. Good Clinical Practice guidelines and the 
Declaration of Helsinki were followed during the course of the study. 
Participants attended three sessions in total. The first session consisted 
of a screening session, at which medical history was reviewed and the 
subject was excluded if any previous or present skin, systemic or neuro-
muscular diseases were present including migraine or chronic tension-
type headache, diabetes, peripheral neuropathies, fibromyalgia, 
myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral 
sclerosis or any other significant disease that may interfere with neuro-
muscular function. In addition, they could not participate if they had 
any severe allergy or history of current or past alcohol and/or drug 
abuse. Female volunteers were not pregnant or experiencing irregular-
ities in their menstrual cycles. They could not be taking any medica-
tion during the sessions, nor could they be participating in another 
experiment. Weight and height were measured, and only participants 
with body mass index between 19 kg/m2 and 35 kg/m2 were included. 
In the screening session, a challenge using the capsaicin pain model 
was also performed to evoke pain and flare. Only subjects who rated 
pain intensity >5 (on a visual analogue scale ranging from 0 to 10) and 
developed a visible flare in response to this challenge were included in 
the present study. Individuals who passed the screening session were 
scheduled for the experimental sessions, at which they first received 
BoNTA and saline (control) injection in each forearm in a random-
ized, blinded fashion; the physician who injected BoNTA and saline 
did not know the content of the syringes and the investigator did not 
receive the code until the end of the trial. The subjects also did not 
know which arm was pretreated with the toxin or the vehicle, which 
was also randomized. All safety precautions were taken during the 
injections. After a one-week interval, which has been shown to be the 
peak of the toxin’s analgesic effect in the authors’ previous experi-
mental pain models in humans (7,44,45), subjects were challenged 
using a topical capsaicin patch (8%) plus mild heat while a microdialy-
sis membrane was placed on the pretreated area. They were asked to 
refrain from ingesting chili peppers 48 h before and caffeine-
containing products 24 h before the experimental session. During the 
study sessions, each volunteer rested in a supine position. An overview 
of the study design is presented in Figure 1. Sensory and vasomotor 
assessments performed for each experimental session are summarized 
in Figure 2. The same investigator (LBS) performed all of the tests at 
the pain laboratory, a quiet environment with a controlled temper-
ature of 22°C to 23°C located in the Center for Sensory-Motor 
Interaction, Aalborg University, Denmark.
BoNTA and saline injections
Each vial of BoNTA (BOTOX®, Allergan Incorporated, USA) was 
reconstituted using preservative-free 0.9% sodium chloride. Each par-
ticipant received a single injection of BOTOX (10 U/0.2 mL) using a 
disposable needle (Neuroline Inoject, 27 gauge, Ambu A/S, Denmark) 
intradermally in the volar part of the forearm, 5 cm distant from the 
cubital fossa, as shown in Figure 3. An equal volume of sterile physio-
logical saline (0.2 mL, 0.9%) was injected in the contralateral forearm 
as a control. The injection side was randomized and blinded. The 
Figure 1) Simplified experimental design showing the time course of all ses-
sions performed. After a screening session, subjects attended a botulinum 
neurotoxin type A (BoNTA) and control pretreatment session. After seven 
days, the experimental session was completed
Figure 2) Schematic diagram showing the timeline, interventions and meas-
urements performed throughout the experimental session. Along with a time 
frame, a line with the condition is outlined to match all nomenclature of the 
events. The baseline represents the measurement before the probe insertion, 
followed by 2 h during which no intervention was performed, referred to as 
the trauma phase. Subsequently, sensitization stimuli with 45°C heat for 
5 min was performed before the capsaicin + 40°C heat treatment, which 
lasted 1 h. Apart from the two heat stimulations, a total of four measure-
ments were made throughout the experiment: sample collection, pain rat-
ings, skin blood flow and skin temperature
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injection sites were mapped on a transparent sheet for further location 
tracking during the microdialysis membrane insertion.
Microdialysis
Two clinically approved, sterile, single-use microdialysis membranes 
for human use were inserted in each arm (66 High Cut Off Linear 
Microdialysis Catheter, 100 kD cut-off, M Dialysis AB, Sweden). The 
two membranes were inserted 1 cm from the pretreatment injection 
site (BoNTA and saline injections), with one on each side. For each 
membrane, a needle was inserted intradermally along 3 cm to intro-
duce the catheter, this being placed in the middle with 1 cm left intact 
from both sides. With the membrane in place, the needle was with-
drawn and the inlet and outlet were secured with a hypoallergenic 
paper tape (Micropore tape, 3M, USA), as shown in detail in Figure 3. 
Afterwards, both membranes were connected to microdialysis pumps 
(107 MD Pump, M Dialysis AB, Sweden). The 107 MD is an adjust-
able pump and was set to 3 µL/min and perfused with a sterile and 
isotonic fluid (Perfusion Fluid T1, M Dialysis AB, Sweden). Samples 
(n=6) were collected every hour for a maximum of 3 h. Although the 
microdialysis technique is considered to be a minimally invasive 
method, the probe insertion in the upper dermis layer is painful and 
can trigger a substantial inflammatory response. Therefore, the tar-
geted tissue needs time to recover from the needle perfusion injury. To 
allow the tissue to recover from the insertion trauma, a period of 2 h 
was given, as recommended (46,47). The recovery of the experimental 
system was evaluated in preliminary trials in human skin with the 
same probe and pump, and at a similar flow rate. 
Capsaicin + mild heat-evoked pain model
Before the application of the capsaicin patch, the area was presensi-
tized with heat stimulation at 45°C for 5 min. Capsaicin patch 8% 
(Qutenza®, Astellas Pharma Europe Ltd.) was then applied to evoke 
pain and flare. The patch size was 6 cm2 (3.84 mg of capsaicin) and 
was placed on the BoNTA- and saline-pretreated areas for 1 h along 
with mild heat (40°C) delivered using the PATHWAY ATS advanced 
thermal stimulator (Medoc Ltd, Israel) through the thermode (30 mm 
× 30 mm), avoiding the microdialysis membrane.
Microdialysis samples
Samples from all subjects were collected and included in the analysis. 
Samples were stored at −80°C for later analysis. 
Measurement of glutamate 
Samples (10 µL) were analyzed for their glutamate content and inves-
tigation of pattern change over the time-course of the trial. An 
ISCUSflex Microdialysis Analyzer (M Dialysis AB, Sweden) was used, 
which applies enzymatic reagents and colorimetric measurements to 
monitor a number of different substances including glutamate. The 
results are presented in µM, as a comparison between the BoNTA- and 
saline-pretreated sides.
Capsaicin + mild heat-evoked pain 
Pain scores were recorded after the membrane insertion, following the 
heat sensitization period and every 15 min from the capsaicin patch 
application. Subjects were asked to rate their pain intensity on a visual 
analogue scale, on which 0 = ‘no pain’ and 10 = ‘the most pain imagin-
able’. The peak pain intensity scores were manually recorded and used 
for statistical analysis.
Skin blood flow
Skin blood flow was measured using a laser speckle contrast imager 
(FLPI, Moor Instruments, United Kingdom) to monitor vasomotor 
changes in the treated area. This device uses a full-field laser tech-
nique and provides real-time and high-resolution images of blood flow. 
The technique is noninvasive and is based on a random speckle pat-
tern that is generated when tissue is illuminated by the laser light to 
capture the movement of the blood cells. With the lenses placed 
40 cm perpendicularly above the tissue, it was possible to obtain an 
image of the entire forearm at baseline, and every hour after the mem-
brane insertion, up to 3 h. To better follow the magnitude of the blood 
flow changes, an area of approximately 9 cm2 was later chosen as a 
region of interest (ROI) for the analysis, which comprised the patch 
surface along with the surrounding area. The software was set to cap-
ture pictures using high resolution/low speed with 1 s per frame in a 
free-run mode. An 8 ms exposure time was selected. The images were 
stored on the computer’s hard disk for offline analysis. The average 
blood flow within the ROI was calculated using the designated Moor 
software (mFLPIV4, Moor Instruments), expressed in arbitrary units 
and used for statistical analysis. Measurements were performed in a 
semidark room to eliminate artifacts from ambient room lighting. 
Skin temperature 
Skin temperature was assessed using a noninvasive infrared thermo-
graphic camera (FLIR Systems Inc, Sweden) to record the surface tis-
sue temperature changes. The temperature resolution of the device is 
0.09°C. The distance between the lenses and the tissue surface was set 
to 50 cm to capture the entire forearm image in a single frame. 
Measurements were performed before the membrane insertion (base-
line) and every hour for 3 h after the insertion. While the baseline 
measurement was performed with the intact and uncovered skin, the 
subsequent measurements were taken after probe insertion or place-
ment of the patch on the cannulated area. To obtain the profile and 
magnitude of temperature changes, a square ROI (approximately 
9 cm2) was defined that comprised the patch surface and the surround-
ing area. Thermographic images were stored on the computer’s hard 
disk for offline analysis. The average temperature within the ROI was 
calculated by ThermaCAM researcher Pro 2.8 (FLIR Systems Inc) and 
used for statistical analysis. To eliminate artifact from ambient room 
lighting, measurements were performed in a semidark room.
Statistical analysis
The number of participants was estimated using the formula 
n = ([2×SD2]/E2) × k, where k was 7.9 constant value, α was set to 0.05 
(corresponding to a significance level of P<0.05) and β was set to 20%, 
corresponding to a statistical power of 0.8 (48). E and SD are the min-
imal clinically relevant difference between the two situations (BoNTA 
Figure 3) Arrows indicate: A distance between the cubital fossa and the 
botulinum neurotoxin type A (BoNTA) injection point (5 cm); B capsaicin 
patch application covering probe 1 and 2; C distance between probes inlet and 
outlet (3 cm); D distance between probe 1 and 2 (1 cm); E BoNTA and 
saline injection point. The figure shows the schematic of the region of interest 
for all interventions. BoNTA (10 U) and control pretreatment injections (E) 
were made approximately 5 cm away from the cubital fossa (A). The guided 
needle was inserted across the skin for 3 cm (C) to facilitate the insertion of the 
probes, which were inserted 1 cm apart from one another (D) with the pre-
treated site in the middle. The capsaicin patch was placed so that it covered 
both probes (B)
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versus saline) and the SD of the mean difference between the two, 
respectively. For a better estimation, data from a previous study (42) 
were used, in which E (for CGRP) was found to be 2.04 (as expected 
to yield a difference of 30%) and SD was found to be 1.7 in a microdi-
alysis study involving human skin. Applying these, the number of 
participants was calculated to be n=10.97. Therefore, 12 subjects were 
recruited to have sufficient number to detect a possible suppressive 
effect of BoNTA in the current study. 
Data are presented as mean and SEM in the text and figures, unless 
otherwise specified. Data were analyzed using ANOVA with three 
factors, defined as: treatment (BoNTA and saline), time (baseline and 
different time points) and sex (male and female). The Bonferroni test 
was used for post hoc analysis. All statistical tests were performed using 
SPSS version 20 (IBM Corporation, USA); P<0.05 was considered to 
be statistically significant.
RESULTS
All volunteers completed the study and no safety issues were reported. 
The main findings were: that BoNTA showed a significant inhibitory 
effect on glutamate release in the skin; and that BoNTA reduced cap-
saicin + mild heat-evoked pain intensity and skin blood flow. None of 
the observed responses were sex dependent.
Glutamate concentration 
Pretreatment with BoNTA significantly reduced capsaicin + mild 
heat-evoked glutamate release compared with saline (F=5.028; 
P<0.05), as shown in Figure 4. Furthermore, post hoc analysis revealed 
a significant interaction between treatment and time in the levels of 
glutamate release in the final samples collected following the capsaicin 
+ mild heat-evoked pain stimulation (F=7.974; P<0.05).
Pain characteristics 
Capsaicin + mild heat-evoked pain intensity was lower in the 
BoNTA-pretreated arm (F=9.894; P<0.01). Moreover, post hoc analy-
sis showed a significant interaction between treatment and time, 
revealing higher pain ratings (F=8.670; P<0.05) during the sensitiza-
tion period, before the membrane insertion and 60 min after the cap-
saicin + heat stimulation, with the BoNTA-pretreated side showing 
lower ratings compared with saline. Detailed information is presented 
in Figure 5.
Skin blood flow
The elevated skin blood flow evoked by capsaicin + mild heat was 
significantly attenuated by BoNTA (F=5.822; P<0.05) compared with 
saline. Post hoc analysis showed a significant interaction between 
treatment time; the response was greatest 3 h after the membrane 
insertion (F=7.113; P<0.05), as shown in Figure 6.
Skin temperature
No significant difference was observed in the skin temperature meas-
urements between BoNTA- and saline-pretreated areas (F=0.008; 
P≥0.05).
Correlation
When comparing all outcomes, a correlation was found between the 
glutamate levels and blood flow (r=0.58; P<0.05). This correlation 
showed that blood flow was higher with higher levels of glutamate. All 
other outcomes did not reveal any correlation.
DISCUSSION 
The present study examined glutamate release following cuta-
neous human experimental pain provoked by capsaicin + mild heat 
before and after localized BoNTA treatment. BoNTA decreased 
pain intensity, suppressed the capsaicin-evoked elevated skin blood 
flow and lowered the release of glutamate. These responses were 
sex-independent. This is the first evidence in humans to show that 
BoNTA attenuates glutamate release in the skin and is consistent with 
previous findings in animals. The blockade of glutamate release may 
contribute to the peripheral analgesic effects of BoNTA.
The effect of BoNTA on glutamate release 
Glutamate is one of the most important excitatory neurotransmitters 
involved in pain transmission, both in the central nervous system and 
in the periphery. Evidence shows that an increased level of glutamate 
is found in inflammatory disease and pain conditions, such as myalgia 
(49), temporal mandibular disorder (39) and chronic tendinitis (41), 
all measured using the microdialysis technique, which enables the col-
lection of fluid samples from the interstitial space of targeted tissues 
through a permeable membrane. Protein-unbound molecules move 
freely from one side of the membrane to the other, based on the con-
centration gradient of these substances (38,50).
In the present study, we used a capsaicin patch (8%) plus mild heat 
as a pain model, which is known to activate polymodal mechanoheat 
receptors located on nociceptive primary C-fibres (51,52). This acti-
vation leads to sensitization and local release of neurotransmitters, 
such as glutamate, CGRP and SP, from the peripheral nerve endings 
(51,52). Here, we demonstrated that provoked glutamate release by 
this pain model was attenuated by BoNTA. In a previous study by our 
group, BoNTA decreased glutamate concentration in the temporalis 
Figure 4) Microdialysis samples were collected 1 h and 2 h following probe 
insertion (trauma phase) and after sensitization and capsaicin (cap) + 40°C 
heat (experimental pain model stimulation) to follow the pattern of gluta-
mate release from the botulinum neurotoxin type A (BoNTA) and control 
sides. The graph shows mean and SEM. *P<0.05
Figure 5) Peak pain was recorded at the probe insertion, sensitization per-
iod (45°C heat for 5 min) and every 15 min for 1 h after the capsaicin and 
40°C heat application. Subjects rated the pain on a visual analogue scale 
from 0 to 10, on which 0 represents ‘no pain’ and 10 ‘the maximum pain 
imaginable’. The graph shows mean and SEM; *P<0.05
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muscle of rats more rapidly and to a greater extent compared with 
saline (53). This effect has also been shown in an animal model of 
formalin-induced pain, in which rats were pretreated with BoNTA and 
challenged with formalin in the paw. Application of BoNTA five days 
before formalin-induced pain led to a significant decrease in glutamate 
release (23). In preclinical settings, it has been shown that substance 
release is blocked by BoNTA through cleavage of synaptosomal-
associated protein 25 (54,55). Based on our observation and some 
previous animal data, it is likely that BoNTA may also influence the 
release of other substances, such as CGRP and SP, from the primary 
afferent neurons. Thus, microdialysis may prove useful for further dis-
coveries and for recording dynamic patterns of substance release (eg, 
CGRP, SP) following BoNTA treatment in human tissue in vivo. In 
rats, it has been shown that some endogenous analgesic compounds 
are elevated following BoNTA administration (56); whether enkeph-
alin, endorphin and/or dynorphin levels are modulated by BoNTA in 
humans, and whether these changes are detectable by microdialysis, 
remains unknown. 
The effect of BoNTA on evoked pain 
The capsaicin patch (8%) plus mild heat applied in the present study 
was found to be a reliable pain model to induce pain and vasomotor 
responses. Capsaicin-sensitive neurons release several neuropeptides, 
such as SP, neurokinin A, somatostatin and CGRP, some of which are 
known to be involved in pain induction and transmission (57). It is 
also known that glutamate receptors, which are present on the primary 
afferent neurons, can be activated by glutamate and provoke pain in 
both animals and humans (35,58).
The inhibitory effect of BoNTA on glutamate release has not only 
been shown in formalin-induced pain in the hind paws of rats (23), 
but also in rat trigeminal nerve cells (29), rabbit iris sphincter and 
dilator muscles (21), and embryonic rat dorsal root ganglia neurons 
(25). Moreover, several animal and human studies have demonstrated 
an analgesic effect of BoNTA (6-8,45,53), while others have not (59-
63). Differences among studies could be due to various reasons. For 
example, the inconsistency of the botulinum toxin types used may be 
one factor. Differences in doses (in units), sites of application (muscle 
or skin), methodology of BoNTA administration, assessment tech-
niques and outcome parameters may also lead to these contradictions. 
In addition, the experimental pain models used in each of these studies 
differ to a large extent. Voller et al (59) used capsaicin-induced pain 
and Krämer et al (63) used electrical-induced pain, while Sycha et al 
(61) used an experimental ultraviolet B pain model.
In the present study, pretreatment with BoNTA significantly 
reduced pain and demonstrated an antinociceptive effect of BoNTA 
on the peripheral nociceptors sensitized by capsaicin and mild heat. 
These results confirm the suitability of the chosen model. Because we 
measured glutamate levels in parallel with pain responses, we were 
interested to determine whether these two parameters are correlated; 
however, the results did not indicate a correlation. Therefore, it is 
assumed that glutamate release inhibition is only partially responsible 
for the analgesic action of BoNTA and other factors/substances are 
potentially involved. 
The effect of BoNTA on vasomotor responses
Capsaicin provokes neurogenic inflammation. This flare can be 
attributed to neuropeptides (eg, CGRP and, to some extent, SP) 
released from peripheral nerve endings (64). These substances are 
released from primary afferents (65). It has been shown that SP is 
colocalized in primary afferent terminals with CGRP and glutamate 
(66). CGRP is a potent vasodilator affecting precapillary arterioles, 
and SP enhances vascular permeability by acting on capillaries and 
postcapillary venules. These substances are involved in the physio-
logical control of blood flow (52,67-69). It is believed that the 40°C 
heat stimulation would enhance these reactions (neuropeptide 
release and vasodilation) through the same receptor involved in the 
capsaicin reaction (transient receptor potential cation channel sub-
family V member 1 [TRPV1]), in addition to the TRPV3 receptor 
(which is insensitive to capsaicin). The latter is known to be present 
on the primary afferent fibres in the skin and is sensitive to heat 
stimulation >39°C (70). Consistent neurogenic inflammation was 
found in the present study, and BoNTA reduced the provoked blood 
flow, as previously observed (7,45). On the contrary, no temperature 
change by BoNTA was detected, which may be a result of the inter-
ference in the irradiated heat while the patch was placed on the skin 
for the final measurement. The plastic-based patch may affect the 
exact temperature or correct recording due to its different compos-
ition compared with the skin. Moreover, a linear association has not 
always been drawn between temperature and blood flow measure-
ments (71). Considering all of these limitations, the blood flow 
reduction by BoNTA adds further support to the concept that skin 
blood flow is a reliable parameter and could be used as an element to 
monitor some aspects of analgesic efficacy in specific candidate com-
pounds. A correlation was found between the reduction of glutamate 
release and blood flow changes following BoNTA pretreatment, sup-
porting the contribution of glutamate in cutaneous vasodilation in 
human skin and the inhibitory role of BoNTA. To determine the role 
of CGRP and SP and potential inhibitory effect of BoNTA, further 
investigation is required to measure the levels of these substances 
along with glutamate levels using the method described in the cur-
rent study.  
CONCLUSIONS
The present study demonstrated that BoNTA attenuated the release of 
glutamate in human skin when provoked by capsaicin + mild heat 
stimulation. BoNTA inhibited the provoked pain and reduced the 
blood flow. An association was found between BoNTA reduction in 
glutamate release and provoked blood flow response.
Figure 6) A Typical blood flow image at baseline, 1 h and 2 h after probe 
insertion, and after sensitization and capsaicin (cap) + 40°C heat stimula-
tion, shown with a corresponding image of the region of interest. The upper 
sequence shows the botulinum neurotoxin type A (BoNTA)-pretreated side 
and the lower sequence shows the matching control. B Blood flow was meas-
ured before probe insertion (baseline) and every hour for 3 h. Assessments 
were made in each arm (BoNTA and control). The graph shows mean and 
SEM; *P<0.05. BoNTA versus control; ###P<0.001, 2 h timepoint versus 
capsaicin + 40°C heat. A correlation was found between the level of gluta-
mate release and blood flow (r=0.58; P<0.05). au Arbitratry units
The effect of BoTNA on glutamate release in humans
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